Contact
searchSearch
HMP Global

Volume 22 - Issue 11 - November 2025

Clinical Editor's Corner
Changing the Present Algorithm of Evaluation and Therapy of Chronic Limb-Threatening Ischemia
11/20/2025
Craig M. Walker, MD, FACC, FACP, FSCAI, FCCP
Dr Walker discusses the article by Zarins and Krievens, "Chronic Limb-Threatening Ischemia: Are We Saving Limbs but Losing Lives?"
Dr Walker discusses the article by Zarins and Krievens, "Chronic Limb-Threatening Ischemia: Are We Saving Limbs but Losing Lives?"
Dr Walker discusses the article...
11/20/2025
Vascular Disease Management
Original Contribution
Chronic Limb-Threatening Ischemia: Are We Saving Limbs but Losing Lives?
11/01/2025
Christopher K. Zarins, MD; Dainis Krievins, MD, PhD
A new strategy based on identifying patients with silent coronary ischemia using coronary CT-derived FFR together with proactive ischemia-targeted coronary revascularization shows promise in reducing adverse cardiac events.
A new strategy based on identifying patients with silent coronary ischemia using coronary CT-derived FFR together with proactive ischemia-targeted coronary revascularization shows promise in reducing adverse cardiac events.
A new strategy based on...
11/01/2025
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

Phase 3 Randomized Clinical Trial
TACE Plus Ablation Improves Survival in Unresectable HCC Compared With TACE Alone
08/11/2026
Laura Simson, MA
Adding selective radiofrequency ablation after transarterial chemoembolization significantly improved survival outcomes among patients with liver-confined, unresectable hepatocellular carcinoma, according to the phase 3 TORCH randomized...
Adding selective radiofrequency ablation after transarterial chemoembolization significantly improved survival outcomes among patients with liver-confined, unresectable hepatocellular carcinoma, according to the phase 3 TORCH randomized...
Adding selective radiofrequency...
08/11/2026
Vascular Disease Management
CANSCAN Participant using VxWave
autonomous Ultrasound Imaging
Vexev Raises $6M to Accelerate U.S. Commercialization of Autonomous Vascular Imaging Platform
08/10/2026
The announcement follows successful results in a multi-site clinical study with U.S. Renal Care, one of the nation's largest dialysis providers, showing early clinical validation of VxWave in routine dialysis clinic workflows.
The announcement follows successful results in a multi-site clinical study with U.S. Renal Care, one of the nation's largest dialysis providers, showing early clinical validation of VxWave in routine dialysis clinic workflows.
The announcement follows...
08/10/2026
Cath Lab Digest
Press Release
Fluidx Completes Submission of Premarket Approval Application for the GPX® Embolic Device
07/24/2026
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
Salt Lake City (UT) – 07/24/2026...
07/24/2026
Vascular Disease Management
Thrombectomy
THUNDER Study Demonstrates Penumbra’s THUNDERBOLT is Safe and Effective for Stroke Care
07/22/2026
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif....
07/22/2026
Cath Lab Digest
Stroke Interventions
Imperative Care Launches Ikon 24 Pro Guidewire, Enhancing the Zoom Stroke System to Support More Efficient Stroke Procedures
07/17/2026
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026...
07/17/2026
Vascular Disease Management
Liver Tumor Ablation
First Meta-analysis Supports Histotripsy for Liver Tumor Ablation
07/14/2026
Laura Simson, MA
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high...
07/14/2026
Vascular Disease Management
Radiation Safety
Landmark Multi-Society Consensus Signals New Era in Occupational Radiation Safety; Rampart Positioned to Accelerate Adoption of Lead-Free Enhanced Radiation Protection
07/14/2026
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026...
07/14/2026
Vascular Disease Management
GPX Embolic Device
GPX® Embolic Device Meets Primary Endpoints in an Investigational Device Exemption (IDE) Pivotal Trial
07/14/2026
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx...
07/14/2026
Vascular Disease Management
Transarterial Chemoembolization
STRIDE-Based Regimens Plus TACE Improve Outcomes vs TACE Alone in Embolization-Eligible Hepatocellular Carcinoma
07/13/2026
Stephanie Holland
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3...
07/13/2026
Vascular Disease Management
Peripheral Intervention
3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA Disease
07/09/2026
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first...
07/09/2026
Cath Lab Digest

November 2025 Volume 22 Issue 11

View Issue Archive
Editorial Correspondence

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use